newsfilter
← Latest News
GlobeNewswire·

LianBio Reports First Quarter 2022 Financial Results and Provides Corporate Update

LianBio's partner, Bristol Myers Squibb, has received U.S. FDA approval of mavacamten for the treatment of patients with obstructive hypertrophic cardiomyopathy (oHCM) Registrational Phase 3 EXPLORER-CN clinical trial of mavacamten in Chinese patients